| Literature DB >> 20454560 |
Christal Worthen1, Bryan C Jensen, Marilyn Parsons.
Abstract
BACKGROUND: The options for treating the fatal disease human African trypanosomiasis are limited to a few drugs that are toxic or facing increasing resistance. New drugs that kill the causative agents, subspecies of Trypanosoma brucei, are therefore urgently needed. Little is known about the cellular mechanisms that lead to death of the pathogenic bloodstream stage. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2010 PMID: 20454560 PMCID: PMC2864271 DOI: 10.1371/journal.pntd.0000678
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Drugs used in this study.
| Compound | Target or effect | Published EC50 | EC50
| EC75 | Reference |
| camptothecin | topoisomerase I | 1.5 µM | 0.55 µM | 0.96 µM |
|
| etoposide | topoisomerase II | n.a. | 2.6 µM | 5.58 µM | n.a. |
| THQ4G | β subunit of PFT | 0.07 µM | 0.25 µM | 0.45 µM | F. Buckner (personal communication) |
| quercetin | induces PCD | 10 µM | 4.8 µM | 8.2 µM |
|
| PGD2 | induces PCD | 3.7 µM | 3.8 µM | 7.4 µM |
|
| pentamidine | unknown | 1.7 nM | 4.4 nM | 7.1 nM |
|
As determined by calcein/ethidium assay after 24 hour treatment (see Figure S1).
The cited study used a 48 hour exposure.
The cited study used a 72 hour exposure.
n.a., no previous reports were found in literature citing an EC50 for etoposide for BF.
Figure 1Analysis of BF viability by flow cytometry.
A) On the left are untreated cells and on the right are cells treated with pentamidine. The top panels show staining with ethidium (dead cells are permeable to the dye) and calcein (live cells hydrolyze the fluorogenic substrate). The bottom panels show the forward and side scatter, with gates drawn to indicate the region containing live cells. B) The pentamidine-treated cells were divided into two populations by forward/side scatter as shown in Figure 1A and analyzed for calcein/ethidium staining.
Plating efficiency following drug treatment.
| Compound | Relative inhibition | % dead cells | Plating efficiency (%) |
| untreated | 4.4 | 95 | |
| camptothecin | 76.9 | 29.5 | 68 |
| etoposide | 65.5 | 23.6 | 23 |
| THQ4G | 69.6 | 20.8 | 8 |
| quercetin | 69.3 | 19.8 | 53 |
| PGD2 | 69.9 | 25.7 | 28 |
| pentamidine | 25.5 | 10.9 | 0.4 |
| pentamidine | 75.8 | 51.9 | <0.02 |
Average decrease in number of live cells as compared to untreated cultures, in multiple plating experiments.
Plating 200 live cells per well (24 wells per experiment) gave rise to no colonies. This number (0.02) assumes the next well would have given rise to a colony.
Figure 2Assays of mitochondrial potential and generation of ROS in drug-treated parasites.
A) Mitochondrial potential. After 24 hour drug treatment, parasites were incubated with rhodamine 123 and analyzed by flow cytometry. Dead cells, which were present in all samples, were excluded by gating on scatter. The arrow marks the midpoint for the untreated control. The legend includes the results from multiple experiments, showing the percentage decrease in number of live cells, average and standard deviation of rhodamine 123 fluorescence expressed as the ratio of the geometric means of the treated samples versus the untreated sample. B) Generation of ROS. Amount of ROS above that seen in untreated cells following a two-hour exposure to the indicated drugs at two different concentrations (see Table 1). ROS were assayed by flow cytometric detection of oxidized CM-H2DCFDA.
ATP levels in drug-treated cells.
| Relative live cell number | Relative ATP | nM ATP±S.D. | |
| camptothecin | 0.22 | 0.78 | 10.40±1.42 |
| etoposide | 0.28 | 0.88 | 11.70±0.63 |
| THQ4G | 0.33 | 0.78 | 10.42±0.52 |
| quercetin | 0.19 | 0.41 | 5.46±1.06 |
| PGD2 | 0.57 | 0.80 | 10.59±0.96 |
| pentamidine | 0.29 | 0.34 | 4.57±0.40 |
| untreated | 1 | 1 | 13.8±2.40 |
Relative live cell number and ATP are in comparison to untreated cells.
Figure 3DNA content and genome segregation following drug treatment.
A) DNA content following 24 hour treatment revealed by PI staining of RNAse treated BF. The large peak at left seen in some samples represents cells with degraded DNA. 2C indicates diploid (G1) DNA content, 4C indicates G2/M DNA content. Note the appearance of cells with sub-G1 DNA (peaks at far left) following some treatments, as well as cells with higher order DNA content. In each case, the total number of live cells was less than 50% of the untreated controls. The percentage of dead cells (%†) is indicated on each graph. B) Duplication and segregation of the nucleus and kinetoplast following drug treatment. The same populations of cells analyzed in Figure 3A were subjected to microscopic analysis, enumerating the number of nuclei and kinetoplasts per cell as revealed by DAPI staining. Forms seen during normal cell cycle progression are indicated by blue shades, while red to yellow shades indicate abnormal, dead end forms. N, nucleus, K, kinetoplast.
Figure 4Annexin V staining of populations with dying cells.
A) Annexin V and PI staining of unfixed cells. Untreated cells show predominantly annexin V-negative, PI-negative staining (lower left quadrant). All drug treated cells showed additional populations with higher annexin staining coupled with low to high PI staining. B) Annexin-positive cells are dead. The pentamidine-treated population shown in A was analyzed according to light scattering properties. The low forward scatter, dead population (D) contained all annexin-stained cells, including those with low to high PI staining. The live population contained the annexin-negative, PI-negative cells.
Figure 5Representative growth curves for RNAi cell lines targeting TOPIBL, NOPP44/46, or TOPIImt.
Tet was added at day 0 to initiate destruction of the targeted RNA. The RNAi-induced cells from the final day of the growth curve were used in the experiments shown in Figure 6. The percent of dead cells at that point is listed. NOPP44/46 protein levels were reduced 44% as shown by immunoblotting (unpublished results).
Figure 6DNA content and genome segregation following genetic knockdown.
The same parasites described in Table 4 were analyzed for DNA content (Panel A) and nuclear and kinetoplast genome segregation (Panel B) as described in Figure 3. The cumulative number of live cells was between 10% and 50% of control uninduced populations on the day assayed.
Effect of depletion of target molecules on parasite growth, viability, mitochondrial potential.
| Gene | Relative live cell number | % dead cells | Relative mito ψ |
|
| n.d. | 35 | 1.10 |
| 0.16 | 28 | 1.34 | |
|
| n.d. | 72 | 1.33 |
| 0.21 | 28 | 0.93 | |
|
| 0.08 | 44 | 0.44 |
| 0.51 | 19 | 0.33 | |
|
| 0.36 | 14 | 0.72 |
| 0.3 | 17 | 0.68 | |
|
| n.d. | 64 | 0.47 |
| 0.26 | 61 | 0.52 | |
|
| 0.05 | 37 | 0.19 |
| 0.15 | 19 | 0.41 | |
|
| 0.04 | 26 | 0.34 |
| 0.12 | 17 | 0.53 |
Defined as the cumulative reduction in live cell number relative to uninduced controls at day of assay. TOP1BS, TOP1BL, and PEX19 knockdowns were assayed on day 2 post induction of RNAi, while PFTB and NOPP44/46 knockdowns were assayed on day 3 and TOPIImt on day 6. KREPA3 was assayed five days after removal of Tet.
as compared to control cells in the same experiment.
Summary of differential effects of drugs and RNAi on T. brucei BF.a
| Drug/RNAi | target | Plating efficiency | Mito potential | ROS | Cell cycle | Nucleus+kDNA |
| campothecin | Top I | − | − | + | + | + |
| etoposide | Top II | + | − | − | +++ | + |
| THQ4G | PFT | +++ | − | − | +++ | +++ |
| pentamidine | ? | +++ | +++ | − | +++ | +++ |
| PGD2 | ? | + | +++ | − | +++ | + |
| quercetin | ? | − | + | + | − | + |
| Reg. knockout | KREPA3 | nd | +++ | − | +++ | +++ |
| RNAi | TOPIImt | nd | +++ | − | +++ | +++ |
| RNAi | TOPIB | nd | − | nd | +++ | +++ |
| RNAi | PFT-β | nd | + | nd | + | + |
| RNAi | NOPP44/46 | nd | +++ | − | +++ | nd |
| RNAi | PEX19 | nd | +++ | − | − | + |
–, no effect; + limited effect; +++, significant effect following RNAi or 24 hour treatment with drugs at IC75 concentration were defined as noted below. Not done, nd.
- plating efficiency: percentage of cells categorized as live by scatter able to form colonies, compared to untreated. Limited effect, 2–5 fold reduction; significant effect, >5-fold reduction.
- mitochondrial potential: limited effect, 30−50% reduction; significant effect, >50% reduction.
- ROS: limited effect, 5−30% increase in CM-H2DCFDA staining; significant effect, greater than 30% increase.
- cell cycle profile among cells with G1 content or greater: limited effect, G1/G2 or S/G1+G2 1.5−2 standard deviations from untreated cells; significant effect, >2 standard deviations from untreated cells.
- Nucleus+kDNA: limited effect, 10−30% cells having abnormal numbers of nuclei or kinetoplasts, significant effect >30% abnormal forms.